Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

WinRho and disseminated intravascular coagulopathy

Claire Kendall and Eric Wooltorton
CMAJ March 14, 2006 174 (6) 767-768; DOI: https://doi.org/10.1503/cmaj.060201
Claire Kendall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: WinRho is a human blood product, Rho(D) immune globulin, widely used to treat immune thrombocytopenic purpura (ITP) and to prevent Rh alloimmunization in pregnant women who are Rh-negative. Recently, however, a case series1 described 6 patients with ITP who were given WinRho who subsequently experienced severe hemolysis and disseminated intravascular coagulation (DIC); 5 of them died. The manufacturer, Cangene, has since issued „Dear Health Care Professional” letters in both Canada and the United States that warn of 9 international reports of this serious adverse effect.2

The drug: WinRho is a gamma globulin fraction of plasma containing antibodies to Rho(D) derived from blood donors. Donated plasma is stringently screened for known pathogens and then filtered to further reduce the risk of transmission of viruses such as hepatitis B and C, HIV and parvovirus.

WinRho is routinely given to Rh-negative women in their third trimester of pregnancy (28 weeks), postpartum (within 72 h) and after possible exposure to Rh-positive blood after pregnancy termination, amniocentesis or abdominal trauma, to prevent maternal Rh-antibody formation and hemolytic disease of the newborn in future pregnancies. WinRho is also used to treat ITP, an autoimmune disorder of increased splenic platelet destruction.

Pregnant women are treated with 120– 300 μg of WinRho, administered intravenously or intramuscularly. Patients with ITP are given a much higher dose, generally 25–50 μg/kg intravenously. Common adverse effects, which often occur within minutes to days after the infusion, include headache, chills and fever, back pain and shaking. Serious but rare adverse effects have included acute respiratory distress syndrome, acute renal insufficiency, acute anemia and hemoglobinuria.3 The recent postmarketing case reports add DIC as another rare but potentially serious adverse effect, which likely starts as hemoglobinemia and hemoglobinuria.

The 6 cases1 reported in the fall of 2005 were all submitted to the US Food and Drug Administration between 1999 and 2004. They involved 4 males and 2 females 12– 85 years of age with ITP; all received doses of 48– 75 μg/kg. Although most patients were discharged feeling well, 4 experienced acute symptoms of hemoglobinemia or hemoglobinuria within 4 hours of receiving the drug (in the other 2 cases, the exact timing was not clear). All 5 patients were adults who died 3–10 days after being treated; their clinical and laboratory findings were consistent with DIC (e.g., increased prothrombin [PT] and partial thromboplastin times [PTT], fibrin degradation [FDP] or split products [FSP] and D-dimer; decreased fibrinogen level), but with no evident cause of DIC other than the drug treatment.

Cangene reports that a total of 9 cases of DIC have been reported internationally (one in Canada). For ITP patients, Cangene estimates the risk of intravascular hemolysis to be less than 1 in 1000; that of DIC, about 1 in 10 000. Patient age, sex and comorbid conditions do not appear to predict the adverse effect; neither do pretreatment renal function or hemoglobin levels, nor concomitant administration of other blood products. Some of the patients in whom DIC manifested had tolerated previous doses of the drug.

There are no known reports of intravascular hemolysis in pregnant women given WinRho.

What to do: Patients who receive WinRho should be warned of the risk of this rare but potentially fatal adverse event and advised to immediately report any „red flag” symptoms or signs (Box 1). Consideration should be given to close monitoring of patients with symptoms of acute hemoglobinemia or hemoglobinuria, anemia and renal insufficiency for signs of DIC. Appropriate laboratory tests include complete blood counts; PT and PTT; direct and indirect bilirubin; measurement of serum creatinine, urea, haptoglobin, lactate dehydrogenase, D-dimer and FDP/FSP; and urine dipstick and microscopic urinalysis.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

It seems wise to advise pregnant patients of the theoretical risks of receiving a blood product.

REFERENCES

  1. 1.↵
    Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Health Canada–endorsed important safety information on WinRho® SDF (Rho (D) immune globulin (human)). Available: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/winrho_nth-aah_e.pdf (accessed 2006 Jan 31).
  3. 3.↵
    WinRho® SDF for injection [product monograph]. Winnipeg: Cangene Corp. Available: www.cangene.com/documents/winrho_monograph_e.pdf (accessed 2006 Jan 31).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (6)
CMAJ
Vol. 174, Issue 6
14 Mar 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
WinRho and disseminated intravascular coagulopathy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
WinRho and disseminated intravascular coagulopathy
Claire Kendall, Eric Wooltorton
CMAJ Mar 2006, 174 (6) 767-768; DOI: 10.1503/cmaj.060201

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
WinRho and disseminated intravascular coagulopathy
Claire Kendall, Eric Wooltorton
CMAJ Mar 2006, 174 (6) 767-768; DOI: 10.1503/cmaj.060201
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Management of γ-hydroxybutyrate intoxication and withdrawal
  • Tuberculous monoarthritis of the knee joint
  • Vulvar condyloma lata as a first presentation of syphilis
Show more Practice

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Drugs: urogenital

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire